Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UPLIFT: Adjuvant Therapy in High-Risk Stage IA-IB NSCLC
NCT06955325Phase 3Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- May 2025
- Primary completion
- Dec 2030
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
01
Overview
Phase 3, randomised, open-label trial of icotinib, rezivertinib, ensartinib and benmelstobart in non-small cell lung cancer (NSCLC) (2 arms), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Disease-Free Survival at 5 years. Planned start May 2025; status: not yet recruiting.
02
Drugs
icotinibrezivertinibensartinibbenmelstobart
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06955325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06955325.